{"id":76211,"date":"2026-10-14T04:43:44","date_gmt":"2026-10-14T04:43:44","guid":{"rendered":"https:\/\/www.stocktargetadvisor.com\/blog\/?p=76211"},"modified":"2026-10-14T04:43:44","modified_gmt":"2026-10-14T04:43:44","slug":"u-s-analyst-updates-october-13th-2026","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/","title":{"rendered":"U.S. Analyst Updates: October 13th, 2026"},"content":{"rendered":"

Analyst Ratings (USA)<\/a><\/h2>\n

Today’s analyst outlook was selectively positive but cautious on valuations. New coverage leaned bullish, with 40 of 57 initiations rated a Buy. Price-target cuts outnumbered increases 189 to 90, with notable reductions across utilities, real estate and financial stocks. Analysts still raised targets for selected technology, life sciences and energy names, pointing to stock-specific opportunities rather than broad optimism.<\/p>\n

Updates (457)<\/strong><\/p>\n

10x Genomics (TXG)<\/strong> \u2014 Stifel Nicolaus set a US$70.00 price target.<\/p>\n

10x Genomics (TXG)<\/strong> \u2014 TD Cowen maintained its Hold rating and raised its price target to US$70.00 from US$47.00.<\/p>\n

AbbVie (ABBV)<\/strong> \u2014 RBC reiterated its Outperform rating with a US$280.00 price target.<\/p>\n

ACADIA Pharmaceuticals (ACAD)<\/strong> \u2014 UBS downgraded its rating to Neutral from Buy and lowered its price target to US$23.00 from US$49.00.<\/p>\n

Adaptive Biotechnologies (ADPT)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$32.00 from US$28.00.<\/p>\n

ADI Global Distribution Inc. Common Stock (ADIG)<\/strong> \u2014 JPMorgan maintained its Neutral rating and lowered its price target to US$20.00 from US$25.00.<\/p>\n

Adobe (ADBE)<\/strong> \u2014 HSBC downgraded its rating to Hold from Buy and lowered its price target to US$267.00 from US$310.00.<\/p>\n

ADT (ADT)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$7.25 from US$7.75.<\/p>\n

Affirm (AFRM)<\/strong> \u2014 Goldman Sachs maintained its Buy rating and lowered its price target to US$103.00 from US$115.00.<\/p>\n

Agilent Technologies (A)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and raised its price target to US$190.00 from US$175.00.<\/p>\n

Agilent Technologies (A)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$196.00 from US$180.00.<\/p>\n

AIR Global (AIIR)<\/strong> \u2014 Cantor Fitzgerald initiated coverage with an Overweight rating and a US$11.03 price target.<\/p>\n

Air Products (APD)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a US$353.00 price target.<\/p>\n

Albemarle (ALB)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a US$109.00 price target.<\/p>\n

Alliant Energy (LNT)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$68.00 from US$73.00.<\/p>\n

Allient (ALNT)<\/strong> \u2014 JPMorgan downgraded its rating to Neutral from Overweight with a US$120.00 price target.<\/p>\n

Alpha Teknova (TKNO)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$11.00 from US$7.00.<\/p>\n

Alpine Income Property Trust (PINE)<\/strong> \u2014 Stifel Nicolaus set a US$21.25 price target.<\/p>\n

Amer Sports (AS)<\/strong> \u2014 Jefferies initiated coverage with a Buy rating and a US$42.00 price target.<\/p>\n

Ameren (AEE)<\/strong> \u2014 KeyCorp maintained its Overweight rating and raised its price target to US$122.00 from US$116.00.<\/p>\n

American Electric (AEP)<\/strong> \u2014 KeyBanc upgraded its rating to Overweight from Sector Weight with a US$133.00 price target.<\/p>\n

American Healthcare REIT (AHR)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$60.00 from US$66.00.<\/p>\n

American Healthcare REIT (AHR)<\/strong> \u2014 Raymond James initiated coverage with a Strong Buy rating and a US$62.00 price target.<\/p>\n

American Healthcare REIT (AHR)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$62.00 from US$63.00.<\/p>\n

American Homes 4 Rent (AMH)<\/strong> \u2014 RBC maintained its Outperform rating and lowered its price target to US$35.00 from US$37.00.<\/p>\n

American Outdoor Brands (AOUT)<\/strong> \u2014 Ladenburg Thalmann initiated coverage with a Buy rating and a US$22.00 price target.<\/p>\n

AMERISAFE (AMSF)<\/strong> \u2014 Truist maintained its Hold rating and lowered its price target to US$27.00 from US$32.00.<\/p>\n

Amgen (AMGN)<\/strong> \u2014 Guggenheim maintained its Neutral rating and lowered its price target to US$378.00 from US$388.00.<\/p>\n

Amrize (AMRZ)<\/strong> \u2014 JPMorgan maintained its Neutral rating and lowered its price target to US$48.00 from US$52.00.<\/p>\n

AngioDynamics (ANGO)<\/strong> \u2014 HC Wainwright maintained its Buy rating and lowered its price target to US$18.00 from US$19.00.<\/p>\n

Anheuser-Busch InBev SA\/NV (BUD)<\/strong> \u2014 TD Cowen maintained its Hold rating and lowered its price target to US$85.00 from US$89.00.<\/p>\n

Apollo Global Management (APO)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$163.00 from US$172.00.<\/p>\n

Appian (APPN)<\/strong> \u2014 Barclays maintained its Underweight rating and raised its price target to US$30.00 from US$26.00.<\/p>\n

Apple Hospitality REIT (APLE)<\/strong> \u2014 Barclays maintained its Equal Weight rating and raised its price target to US$18.00 from US$17.00.<\/p>\n

Applied Aerospace & Defense (AADX)<\/strong> \u2014 RBC maintained its Outperform rating and lowered its price target to US$21.00 from US$24.00.<\/p>\n

Applied Materials (AMAT)<\/strong> \u2014 Cantor Fitzgerald reiterated its Outperform rating.<\/p>\n

AppLovin (APP)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$400.00 from US$450.00.<\/p>\n

Arch Capital (ACGL)<\/strong> \u2014 Morgan Stanley downgraded its rating to Equal-Weight from Overweight and lowered its price target to US$100.00 from US$105.00.<\/p>\n

Ares Management (ARES)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$134.00 from US$142.00.<\/p>\n

Aritzia (ATZAF)<\/strong> \u2014 Jefferies downgraded its rating to Hold from Buy.<\/p>\n

Ascentage Pharma (AAPG)<\/strong> \u2014 Citizens initiated coverage with a Mkt Outperform rating and a US$35.00 price target.<\/p>\n

Ascentage Pharma Group International (AAPG)<\/strong> \u2014 Citigroup initiated coverage with an Outperform rating.<\/p>\n

AST SpaceMobile (ASTS)<\/strong> \u2014 Piper Sandler downgraded its rating to Neutral from Overweight and lowered its price target to US$54.00 from US$98.00.<\/p>\n

Astrazeneca (AZN)<\/strong> \u2014 Nordea Equity Research upgraded its rating to Buy from Sell.<\/p>\n

AT&T (T)<\/strong> \u2014 Bernstein downgraded its rating to Mkt Perform from Outperform with a US$24.00 price target.<\/p>\n

Atlas Copco (ATLKY)<\/strong> \u2014 Citigroup reiterated its Buy rating.<\/p>\n

Atlassian (TEAM)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$222.00 from US$172.00.<\/p>\n

Avantor (AVTR)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and raised its price target to US$15.00 from US$14.00.<\/p>\n

Avantor (AVTR)<\/strong> \u2014 TD Cowen maintained its Hold rating and raised its price target to US$17.00 from US$15.00.<\/p>\n

Avient (AVNT)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a US$44.00 price target.<\/p>\n

Axalta Coating Systems (AXTA)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a US$45.00 price target.<\/p>\n

Axon Enterprise (AXON)<\/strong> \u2014 TD Cowen reiterated its Buy rating.<\/p>\n

Badger Meter (BMI)<\/strong> \u2014 Barclays maintained its Underweight rating and lowered its price target to US$111.00 from US$112.00.<\/p>\n

Ball (BALL)<\/strong> \u2014 RBC maintained its Outperform rating and lowered its price target to US$73.00 from US$77.00.<\/p>\n

BBVA Banco Frances (BBAR)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$15.00 from US$20.00.<\/p>\n

BCE (BCE)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$24.00 from US$25.00.<\/p>\n

BCE Inc (BCE)<\/strong> \u2014 Canaccord Genuity upgraded its rating to Buy from Hold.<\/p>\n

Bel Fuse (BELFB)<\/strong> \u2014 JPMorgan maintained its Overweight rating and lowered its price target to US$330.00 from US$380.00.<\/p>\n

BellRing Brands (BRBR)<\/strong> \u2014 TD Cowen maintained its Hold rating and lowered its price target to US$9.00 from US$12.00.<\/p>\n

Better Home & Finance (BETR)<\/strong> \u2014 Needham & Company LLC maintained its Buy rating and lowered its price target to US$15.00 from US$25.00.<\/p>\n

BHP Group (BHP)<\/strong> \u2014 Citigroup reiterated its Neutral rating.<\/p>\n

Biodesix (BDSX)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$40.00 from US$30.00.<\/p>\n

BlackRock (BLK)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$1,468.00 from US$1,479.00.<\/p>\n

Blackstone (BX)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$116.00 from US$122.00.<\/p>\n

Bloom Energy (BE)<\/strong> \u2014 Roth Capital reiterated its Neutral rating with a US$260.00 price target.<\/p>\n

Bob’s Discount Furniture (BOBS)<\/strong> \u2014 Evercore set a US$18.00 price target.<\/p>\n

Boot Barn (BOOT)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$180.00 from US$205.00.<\/p>\n

Boston Scientific (BSX)<\/strong> \u2014 Mizuho set a US$55.00 price target.<\/p>\n

Boyd Gaming (BYD)<\/strong> \u2014 Citigroup reiterated its Market Perform rating.<\/p>\n

Boyd Gaming (BYD)<\/strong> \u2014 Goldman Sachs set a US$80.00 price target.<\/p>\n

Bright Horizons Family Solutions (BFAM)<\/strong> \u2014 Morgan Stanley maintained its Underweight rating and lowered its price target to US$64.00 from US$66.00.<\/p>\n

BrightView (BV)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$11.50 from US$12.50.<\/p>\n

Bristol Myers Squibb (BMY)<\/strong> \u2014 Bernstein reiterated its Market Perform rating.<\/p>\n

Bristol Myers Squibb (BMY)<\/strong> \u2014 Wells Fargo & Company maintained its Equal Weight rating and lowered its price target to US$60.00 from US$65.00.<\/p>\n

Brookfield Asset Management (BAM)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$49.00 from US$55.00.<\/p>\n

Brookfield Infrastructure (BIPC)<\/strong> \u2014 Morgan Stanley maintained its Underweight rating and lowered its price target to US$48.00 from US$50.00.<\/p>\n

Brookfield Infrastructure Partners (BIP)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$48.00 from US$50.00.<\/p>\n

Brookfield Renewable (BEPC)<\/strong> \u2014 Morgan Stanley maintained its Underweight rating and lowered its price target to US$37.00 from US$42.00.<\/p>\n

Brookfield Renewable Partners (BEP)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$37.00 from US$42.00.<\/p>\n

Bruker (BRKR)<\/strong> \u2014 TD Cowen maintained its Hold rating and raised its price target to US$62.00 from US$60.00.<\/p>\n

BWX Technologies (BWXT)<\/strong> \u2014 JPMorgan maintained its Overweight rating and lowered its price target to US$190.00 from US$230.00.<\/p>\n

Cadre (CDRE)<\/strong> \u2014 JPMorgan maintained its Overweight rating and lowered its price target to US$35.00 from US$45.00.<\/p>\n

CAE (CAE)<\/strong> \u2014 Jefferies maintained its Hold rating and lowered its price target to US$26.00 from US$28.00.<\/p>\n

Camden Property Trust (CPT)<\/strong> \u2014 RBC maintained its Sector Perform rating and lowered its price target to US$101.00 from US$111.00.<\/p>\n

Camping World (CWH)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$7.00 from US$8.00.<\/p>\n

Cardinal Energy (CRLFF)<\/strong> \u2014 RBC downgraded its rating to Sector Perform from Outperform.<\/p>\n

CareTrust REIT (CTRE)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

CareTrust REIT (CTRE)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$44.00 from US$48.00.<\/p>\n

CareTrust REIT (CTRE)<\/strong> \u2014 Wedbush set a US$44.00 price target.<\/p>\n

Caris Life Sciences (CAI)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$36.00 from US$30.00.<\/p>\n

Carlisle Companies (CSL)<\/strong> \u2014 Baird maintained its Outperform rating and lowered its price target to US$402.00 from US$412.00.<\/p>\n

Carlyle Group (CG)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$60.00 from US$70.00.<\/p>\n

Carnival (CCL)<\/strong> \u2014 Tigress Financial reiterated its Buy rating with a US$42.00 price target.<\/p>\n

CECO Environmental (CECO)<\/strong> \u2014 JPMorgan maintained its Overweight rating and lowered its price target to US$110.00 from US$130.00.<\/p>\n

Celanese (CE)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a US$49.00 price target.<\/p>\n

Celanese (CE)<\/strong> \u2014 RBC maintained its Sector Perform rating and raised its price target to US$46.00 from US$45.00.<\/p>\n

Celsius (CELH)<\/strong> \u2014 TD Cowen maintained its Buy rating and lowered its price target to US$35.00 from US$41.00.<\/p>\n

CenterPoint Energy (CNP)<\/strong> \u2014 JPMorgan maintained its Neutral rating and lowered its price target to US$44.00 from US$46.00.<\/p>\n

CenterPoint Energy (CNP)<\/strong> \u2014 KeyCorp maintained its Overweight rating and lowered its price target to US$44.00 from US$46.00.<\/p>\n

Certara (CERT)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$11.00 from US$9.00.<\/p>\n

Charles Schwab (SCHW)<\/strong> \u2014 Truist maintained its Buy rating and lowered its price target to US$125.00 from US$130.00.<\/p>\n

Chemours (CC)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a US$16.00 price target.<\/p>\n

Chemours (CC)<\/strong> \u2014 RBC downgraded its rating to Sector Perform from Outperform with a US$14.00 price target.<\/p>\n

Churchill Downs (CHDN)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

Churchill Downs (CHDN)<\/strong> \u2014 Citizens maintained its Market Outperform rating and lowered its price target to US$131.00 from US$137.00.<\/p>\n

Churchill Downs (CHDN)<\/strong> \u2014 RBC set a US$131.00 price target.<\/p>\n

Citigroup (C)<\/strong> \u2014 Loop Capital set a US$155.00 price target.<\/p>\n

Citizens (CIZN)<\/strong> \u2014 Citigroup changed its rating to Market Outperform from Market Perform.<\/p>\n

Clorox (CLX)<\/strong> \u2014 TD Cowen maintained its Hold rating and lowered its price target to US$80.00 from US$85.00.<\/p>\n

Cloudflare (NET)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$375.00 from US$355.00.<\/p>\n

CoastalSouth Bancshares (COSO)<\/strong> \u2014 Brean Capital initiated coverage with a Buy rating and a US$33.00 price target.<\/p>\n

Cognizant Technology Solutions (CTSH)<\/strong> \u2014 TD Cowen maintained its Hold rating and raised its price target to US$60.00 from US$54.00.<\/p>\n

Coinbase Global (COIN)<\/strong> \u2014 Citigroup maintained its Buy rating and raised its price target to US$230.00 from US$210.00.<\/p>\n

Columbia Banking (COLB)<\/strong> \u2014 Deutsche Bank initiated coverage with a Hold rating and a US$32.00 price target.<\/p>\n

Comcast (CMCSA)<\/strong> \u2014 Bernstein reiterated its Market Perform rating with a US$23.00 price target.<\/p>\n

Compass Diversified (CODI)<\/strong> \u2014 Compass Point set a US$17.00 price target.<\/p>\n

Compass Diversified (CODI)<\/strong> \u2014 Ladenburg Thalmann initiated coverage with a Buy rating and a US$17.00 price target.<\/p>\n

Consolidated Edison (ED)<\/strong> \u2014 KeyCorp maintained its Underweight rating and lowered its price target to US$87.00 from US$94.00.<\/p>\n

Contineum Therapeutics (CTNM)<\/strong> \u2014 Baird downgraded its rating to Neutral from Outperform with a US$14.00 price target.<\/p>\n

CRH (CRH)<\/strong> \u2014 JPMorgan maintained its Overweight rating and lowered its price target to US$115.00 from US$140.00.<\/p>\n

CryoPort (CYRX)<\/strong> \u2014 Baird set a US$26.00 price target.<\/p>\n

CryoPort (CYRX)<\/strong> \u2014 BTIG Research maintained its Buy rating and raised its price target to US$26.00 from US$25.00.<\/p>\n

CryoPort (CYRX)<\/strong> \u2014 Piper Sandler upgraded its rating to Buy.<\/p>\n

CytomX Therapeutics (CTMX)<\/strong> \u2014 Cantor Fitzgerald reiterated its Overweight rating.<\/p>\n

Danaher (DHR)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$255.00 from US$236.00.<\/p>\n

Datadog (DDOG)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$300.00 from US$290.00.<\/p>\n

DexCom (DXCM)<\/strong> \u2014 Mizuho set a US$100.00 price target.<\/p>\n

Diamondback Energy (FANG)<\/strong> \u2014 Stephens reiterated its Outperform rating.<\/p>\n

DigitalOcean (DOCN)<\/strong> \u2014 KeyCorp reiterated its Overweight rating.<\/p>\n

Domino’s Pizza (DPZ)<\/strong> \u2014 TD Cowen reiterated its Hold rating with a US$320.00 price target.<\/p>\n

Dow (DOW)<\/strong> \u2014 Barclays initiated coverage with an Underweight rating and a US$30.00 price target.<\/p>\n

Duke Energy (DUK)<\/strong> \u2014 JPMorgan maintained its Neutral rating and lowered its price target to US$130.00 from US$137.00.<\/p>\n

Duke Energy (DUK)<\/strong> \u2014 KeyCorp maintained its Overweight rating and lowered its price target to US$128.00 from US$139.00.<\/p>\n

DuPont (DD)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a US$156.00 price target.<\/p>\n

Dynatrace (DT)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$71.00 from US$60.00.<\/p>\n

Eagle Materials (EXP)<\/strong> \u2014 JPMorgan maintained its Neutral rating and lowered its price target to US$200.00 from US$225.00.<\/p>\n

EagleRock Land (EROK)<\/strong> \u2014 JPMorgan maintained its Overweight rating and lowered its price target to US$27.00 from US$29.00.<\/p>\n

Eastman Chemical (EMN)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a US$72.00 price target.<\/p>\n

Eastman Chemical (EMN)<\/strong> \u2014 RBC maintained its Sector Perform rating and lowered its price target to US$65.00 from US$74.00.<\/p>\n

Electra Therapeutics (ETRA)<\/strong> \u2014 Cantor Fitzgerald initiated coverage with an Overweight rating.<\/p>\n

Electra Therapeutics (ETRA)<\/strong> \u2014 Evercore initiated coverage with an Outperform rating and a US$36.00 price target.<\/p>\n

Electra Therapeutics (ETRA)<\/strong> \u2014 Jefferies initiated coverage with a Buy rating and a US$32.00 price target.<\/p>\n

Electra Therapeutics (ETRA)<\/strong> \u2014 TD Cowen initiated coverage with a Buy rating.<\/p>\n

Element Solutions (ESI)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a US$53.00 price target.<\/p>\n

Encore Capital Group (ECPG)<\/strong> \u2014 Northland Securities set a US$124.00 price target.<\/p>\n

Enerflex (EFXT)<\/strong> \u2014 CIBC upgraded its rating to Sector Outperform from Neutral with a US$35.00 price target.<\/p>\n

Energy Transfer (ET)<\/strong> \u2014 Mizuho set a US$26.00 price target.<\/p>\n

Enlight Renewable Energy (ENLT)<\/strong> \u2014 Mizuho maintained its Underperform rating and lowered its price target to US$41.00 from US$45.00.<\/p>\n

Enovix (ENVX)<\/strong> \u2014 Northland Securities set a US$5.00 price target.<\/p>\n

Entegris (ENTG)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a US$212.00 price target.<\/p>\n

Entergy (ETR)<\/strong> \u2014 JPMorgan maintained its Overweight rating and lowered its price target to US$130.00 from US$137.00.<\/p>\n

Entergy (ETR)<\/strong> \u2014 KeyCorp maintained its Overweight rating and lowered its price target to US$118.00 from US$123.00.<\/p>\n

Envoy Medical (COCH)<\/strong> \u2014 HC Wainwright reiterated its Buy rating.<\/p>\n

Equifax (EFX)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$205.00 from US$225.00.<\/p>\n

Equifax (EFX)<\/strong> \u2014 Needham & Company LLC maintained its Buy rating and lowered its price target to US$190.00 from US$245.00.<\/p>\n

Equity Lifestyle Properties (ELS)<\/strong> \u2014 RBC maintained its Outperform rating and lowered its price target to US$68.00 from US$71.00.<\/p>\n

Ero Copper (ERO)<\/strong> \u2014 Scotiabank downgraded its rating to Sector Perform from Sector Outperform.<\/p>\n

Escalade (ESCA)<\/strong> \u2014 Ladenburg Thalmann initiated coverage with a Neutral rating.<\/p>\n

ESCO Technologies (ESE)<\/strong> \u2014 JPMorgan maintained its Overweight rating and lowered its price target to US$350.00 from US$420.00.<\/p>\n

Essex Property Trust (ESS)<\/strong> \u2014 RBC maintained its Outperform rating and lowered its price target to US$298.00 from US$312.00.<\/p>\n

eToro Group (ETOR)<\/strong> \u2014 Susquehanna maintained its Positive rating and lowered its price target to US$46.00 from US$51.00.<\/p>\n

Evergy (EVRG)<\/strong> \u2014 BMO Capital Markets maintained its Outperform rating and lowered its price target to US$85.00 from US$89.00.<\/p>\n

Evergy (EVRG)<\/strong> \u2014 DA Davidson set a US$85.00 price target.<\/p>\n

Exagen (XGN)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$11.00 from US$10.00.<\/p>\n

Exelon (EXC)<\/strong> \u2014 KeyBanc upgraded its rating to Sector Weight from Underweight.<\/p>\n

FactSet Research Systems (FDS)<\/strong> \u2014 BMO Capital Markets maintained its Market Perform rating and raised its price target to US$314.00 from US$300.00.<\/p>\n

Fair Isaac (FICO)<\/strong> \u2014 Needham & Company LLC maintained its Buy rating and lowered its price target to US$1,100.00 from US$1,650.00.<\/p>\n

Fair Isaac (FICO)<\/strong> \u2014 Raymond James maintained its Outperform rating and lowered its price target to US$1,230.00 from US$1,750.00.<\/p>\n

Fastenal (FAST)<\/strong> \u2014 DA Davidson set a US$51.00 price target.<\/p>\n

Fidelity National Information Services (FIS)<\/strong> \u2014 Goldman Sachs maintained its Buy rating and lowered its price target to US$44.00 from US$52.00.<\/p>\n

Fidelity National Information Services (FIS)<\/strong> \u2014 Susquehanna maintained its Neutral rating and lowered its price target to US$37.00 from US$46.00.<\/p>\n

First Tracks Biotherapeutics (TRAX)<\/strong> \u2014 Canaccord Genuity maintained its Buy rating and raised its price target to US$60.00 from US$50.00.<\/p>\n

First Tracks Biotherapeutics (TRAX)<\/strong> \u2014 Evercore reiterated its Outperform rating with a US$70.00 price target.<\/p>\n

FirstEnergy (FE)<\/strong> \u2014 New Street Research set a US$47.00 price target.<\/p>\n

Five9 (FIVN)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$40.00 from US$34.00.<\/p>\n

Floor & Decor (FND)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$49.00 from US$59.00.<\/p>\n

Floor & Decor (FND)<\/strong> \u2014 Evercore set a US$50.00 price target.<\/p>\n

Flutter Entertainment (FLUT)<\/strong> \u2014 Citizens maintained its Market Outperform rating and lowered its price target to US$129.00 from US$145.00.<\/p>\n

FMC (FMC)<\/strong> \u2014 Mizuho maintained its Outperform rating and lowered its price target to US$12.00 from US$15.00.<\/p>\n

Foghorn Therapeutics (FHTX)<\/strong> \u2014 Evercore downgraded its rating to In-line from Outperform with a US$3.00 price target.<\/p>\n

FormFactor (FORM)<\/strong> \u2014 Stifel Nicolaus set a US$115.00 price target.<\/p>\n

Fortinet (FTNT)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$225.00 from US$215.00.<\/p>\n

Freshpet (FRPT)<\/strong> \u2014 TD Cowen maintained its Buy rating and lowered its price target to US$80.00 from US$85.00.<\/p>\n

Freshworks (FRSH)<\/strong> \u2014 Cantor Fitzgerald reiterated its Overweight rating.<\/p>\n

Galaxy Digital (GLXY)<\/strong> \u2014 Citigroup upgraded its rating to Buy from Neutral and raised its price target to US$28.00 from US$26.00.<\/p>\n

Galp Energia SGPS (GLPEY)<\/strong> \u2014 Citigroup reiterated its Neutral rating.<\/p>\n

Gartner (IT)<\/strong> \u2014 BMO Capital Markets maintained its Market Perform rating and raised its price target to US$212.00 from US$206.00.<\/p>\n

GE Vernova (GEV)<\/strong> \u2014 Guggenheim reiterated its Buy rating with a US$1,450.00 price target.<\/p>\n

Gemini Space Station (GEMI)<\/strong> \u2014 Citigroup upgraded its rating to Neutral from Sell and raised its price target to US$4.75 from US$3.20.<\/p>\n

Genesis Energy (GEL)<\/strong> \u2014 RBC maintained its Outperform rating and lowered its price target to US$17.00 from US$18.00.<\/p>\n

Ginkgo Bioworks (DNA)<\/strong> \u2014 TD Cowen maintained its Hold rating and raised its price target to US$11.00 from US$9.00.<\/p>\n

Glaukos (GKOS)<\/strong> \u2014 Mizuho set a US$190.00 price target.<\/p>\n

Globant (GLOB)<\/strong> \u2014 Wells Fargo resumed coverage with an Equal Weight rating and a US$39.00 price target.<\/p>\n

Globant (GLOB)<\/strong> \u2014 Wells Fargo & Company initiated coverage with an Equal Weight rating and lowered its price target to US$39.00 from US$42.00.<\/p>\n

Goosehead Insurance (GSHD)<\/strong> \u2014 Truist maintained its Hold rating and lowered its price target to US$48.00 from US$58.00.<\/p>\n

Gossamer Bio (GOSS)<\/strong> \u2014 Chardan initiated coverage with a Buy rating and a US$160.00 price target.<\/p>\n

GRAIL (GRAL)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$180.00 from US$88.00.<\/p>\n

Graphic Packaging (GPK)<\/strong> \u2014 RBC maintained its Sector Perform rating and lowered its price target to US$9.00 from US$10.00.<\/p>\n

Grupo Financiero Galicia (GGAL)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$45.00 from US$60.00.<\/p>\n

Halozyme Therapeutics (HALO)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$130.00 from US$105.00.<\/p>\n

Hamilton Lane (HLNE)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$115.00 from US$131.00.<\/p>\n

Harmony Biosciences (HRMY)<\/strong> \u2014 HC Wainwright reiterated its Buy rating with a US$55.00 price target.<\/p>\n

Hasbro (HAS)<\/strong> \u2014 Citigroup maintained its Buy rating and raised its price target to US$117.00 from US$107.00.<\/p>\n

Hawkins (HWKN)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$141.00 from US$142.00.<\/p>\n

Healthcare Realty Trust (HR)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$18.00 from US$21.00.<\/p>\n

Healthpeak Properties (DOC)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$21.00 from US$24.00.<\/p>\n

Healthpeak Properties (DOC)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$20.00 from US$21.50.<\/p>\n

Hershey (HSY)<\/strong> \u2014 TD Cowen maintained its Buy rating and lowered its price target to US$198.00 from US$210.00.<\/p>\n

Hess Midstream Partners (HESM)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$33.00 from US$37.00.<\/p>\n

Hess Midstream Partners (HESM)<\/strong> \u2014 Morgan Stanley maintained its Underweight rating and lowered its price target to US$30.00 from US$39.00.<\/p>\n

Hess Midstream Partners (HESM)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$34.00 from US$37.00.<\/p>\n

Host Hotels & Resorts (HST)<\/strong> \u2014 Barclays maintained its Equal Weight rating and raised its price target to US$25.00 from US$24.00.<\/p>\n

Humana (HUM)<\/strong> \u2014 Mizuho maintained its Outperform rating and raised its price target to US$495.00 from US$468.00.<\/p>\n

Huntsman (HUN)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a US$10.00 price target.<\/p>\n

Huntsman (HUN)<\/strong> \u2014 RBC maintained its Sector Perform rating and lowered its price target to US$9.00 from US$10.00.<\/p>\n

Hyatt Hotels (H)<\/strong> \u2014 Susquehanna maintained its Neutral rating and lowered its price target to US$180.00 from US$185.00.<\/p>\n

Illumina (ILMN)<\/strong> \u2014 TD Cowen maintained its Hold rating and raised its price target to US$270.00 from US$210.00.<\/p>\n

Immatics (IMTX)<\/strong> \u2014 Stifel Nicolaus set a US$15.00 price target.<\/p>\n

Incyte (INCY)<\/strong> \u2014 Benchmark reiterated its Buy rating.<\/p>\n

Incyte (INCY)<\/strong> \u2014 HC Wainwright reiterated its Buy rating with a US$152.00 price target.<\/p>\n

Inhibikase Therapeutics (IKT)<\/strong> \u2014 Chardan initiated coverage with a Neutral rating and a US$1.50 price target.<\/p>\n

Inspire Medical Systems (INSP)<\/strong> \u2014 Mizuho set a US$75.00 price target.<\/p>\n

Inspired Entertainment (INSE)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

Inspired Entertainment (INSE)<\/strong> \u2014 Citizens maintained its Market Outperform rating and lowered its price target to US$9.00 from US$11.00.<\/p>\n

International Business Machines (IBM)<\/strong> \u2014 RBC reiterated its Outperform rating with a US$270.00 price target.<\/p>\n

International Business Machines (IBM)<\/strong> \u2014 UBS reiterated its Neutral rating.<\/p>\n

Intuitive Surgical (ISRG)<\/strong> \u2014 Mizuho set a US$415.00 price target.<\/p>\n

Intuitive Surgical (ISRG)<\/strong> \u2014 UBS reiterated its Buy rating.<\/p>\n

Invesco (IVZ)<\/strong> \u2014 BMO Capital Markets maintained its Outperform rating and raised its price target to US$36.00 from US$34.00.<\/p>\n

Invesco (IVZ)<\/strong> \u2014 UBS set a US$36.00 price target.<\/p>\n

Invitation Home (INVH)<\/strong> \u2014 RBC maintained its Sector Perform rating and lowered its price target to US$29.00 from US$31.00.<\/p>\n

IonQ (IONQ)<\/strong> \u2014 Rosenblatt Securities reiterated its Buy rating with a US$100.00 price target.<\/p>\n

IonQ (IONQ)<\/strong> \u2014 Wedbush reiterated its Outperform rating with a US$75.00 price target.<\/p>\n

Iovance Biotherapeutics (IOVA)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$18.00 from US$15.00.<\/p>\n

IRSA Inversiones (IRS)<\/strong> \u2014 BofA Securities initiated coverage with a Buy rating and a US$23.60 price target.<\/p>\n

James Hardie Industries (JHX)<\/strong> \u2014 Baird maintained its Outperform rating and lowered its price target to US$32.00 from US$34.00.<\/p>\n

JAN (JAN)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$33.00 from US$34.00.<\/p>\n

JD.com (JD)<\/strong> \u2014 BofA Securities maintained its Buy rating and lowered its price target to US$37.00 from US$38.00.<\/p>\n

JPMorgan Chase & Co. (JPM)<\/strong> \u2014 Goldman Sachs reiterated its Outperform rating with a US$392.00 price target.<\/p>\n

Kimberly-Clark (KMB)<\/strong> \u2014 TD Cowen maintained its Hold rating and lowered its price target to US$97.00 from US$104.00.<\/p>\n

Kinetik (KNTK)<\/strong> \u2014 Barclays maintained its Equal Weight rating and raised its price target to US$56.00 from US$51.00.<\/p>\n

KKR & Co. Inc. (KKR)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$122.00 from US$123.00.<\/p>\n

Knife River (KNF)<\/strong> \u2014 JPMorgan maintained its Underweight rating and lowered its price target to US$63.00 from US$73.00.<\/p>\n

Knight-Swift Transportation (KNX)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$82.00 from US$94.00.<\/p>\n

Kroger (KR)<\/strong> \u2014 UBS reiterated its Neutral rating.<\/p>\n

Kyntra Bio (KYNB)<\/strong> \u2014 Maxim initiated coverage with a Buy rating and a US$35.00 price target.<\/p>\n

Lantheus Holdings (LNTH)<\/strong> \u2014 Mizuho downgraded its rating to Neutral from Outperform and lowered its price target to US$109.00 from US$115.00.<\/p>\n

Las Vegas Sands (LVS)<\/strong> \u2014 Goldman Sachs reiterated its Buy rating with a US$47.00 price target.<\/p>\n

Lazard (LAZ)<\/strong> \u2014 Goldman Sachs maintained its Sell rating and lowered its price target to US$32.00 from US$36.00.<\/p>\n

Legend Biotech (LEGN)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$68.00 from US$74.00.<\/p>\n

Liftoff Mobile (LFTO)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$20.00 from US$30.00.<\/p>\n

Linde plc (LIN)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a US$577.00 price target.<\/p>\n

Live Nation Entertainment (LYV)<\/strong> \u2014 Bernstein reiterated its Outperform rating with a US$220.00 price target.<\/p>\n

Logitech International (LOGI)<\/strong> \u2014 JPMorgan maintained its Neutral rating and lowered its price target to US$94.00 from US$102.00.<\/p>\n

LPL Financial (LPLA)<\/strong> \u2014 Truist set a US$354.00 price target.<\/p>\n

LyondellBasell (LYB)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a US$66.00 price target.<\/p>\n

LyondellBasell Industries (LYB)<\/strong> \u2014 RBC maintained its Outperform rating and lowered its price target to US$68.00 from US$72.00.<\/p>\n

Macro Bank (BMA)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$90.00 from US$130.00.<\/p>\n

ManpowerGroup (MAN)<\/strong> \u2014 UBS maintained its Neutral rating and raised its price target to US$56.00 from US$55.00.<\/p>\n

Marathon Petroleum (MPC)<\/strong> \u2014 Citigroup maintained its Neutral rating and raised its price target to US$518.00 from US$318.00.<\/p>\n

Martin Marietta Materials (MLM)<\/strong> \u2014 JPMorgan maintained its Overweight rating and lowered its price target to US$650.00 from US$680.00.<\/p>\n

Matson (MATX)<\/strong> \u2014 JPMorgan maintained its Overweight rating and raised its price target to US$310.00 from US$270.00.<\/p>\n

Mattel (MAT)<\/strong> \u2014 Citigroup maintained its Neutral rating and raised its price target to US$17.00 from US$15.00.<\/p>\n

MDA Space (MDA)<\/strong> \u2014 Jefferies reiterated its Buy rating.<\/p>\n

MercadoLibre (MELI)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$2,100.00 from US$2,150.00.<\/p>\n

Meta Platforms (META)<\/strong> \u2014 KeyCorp reiterated its Overweight rating with a US$900.00 price target.<\/p>\n

Meta Platforms (META)<\/strong> \u2014 Pivotal Research maintained its Buy rating and raised its price target to US$930.00 from US$790.00.<\/p>\n

Meta Platforms (META)<\/strong> \u2014 Rosenblatt Securities reiterated its Buy rating with a US$886.00 price target.<\/p>\n

Meta Platforms (META)<\/strong> \u2014 Truist maintained its Buy rating and raised its price target to US$1,000.00 from US$763.00.<\/p>\n

Mettler-Toledo International (MTD)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and raised its price target to US$1,575.00 from US$1,450.00.<\/p>\n

MGM Resorts International (MGM)<\/strong> \u2014 Goldman Sachs set a US$30.00 price target.<\/p>\n

Micron Technology (MU)<\/strong> \u2014 Rosenblatt Securities reiterated its Buy rating with a US$1,900.00 price target.<\/p>\n

Microsoft (MSFT)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$600.00 from US$512.00.<\/p>\n

Mid-America Apartment Communities (MAA)<\/strong> \u2014 RBC maintained its Sector Perform rating and lowered its price target to US$127.00 from US$138.00.<\/p>\n

MiniMed (MMED)<\/strong> \u2014 Rothschild & Co Redburn initiated coverage with a Buy rating and a US$30.00 price target.<\/p>\n

Mirum Pharmaceuticals (MIRM)<\/strong> \u2014 Evercore reiterated its Outperform rating with a US$146.00 price target.<\/p>\n

Molson Coors Beverage (TAP)<\/strong> \u2014 TD Cowen maintained its Hold rating and lowered its price target to US$37.00 from US$43.00.<\/p>\n

MongoDB (MDB)<\/strong> \u2014 Needham & Company LLC reiterated its Buy rating with a US$430.00 price target.<\/p>\n

Moody’s (MCO)<\/strong> \u2014 BMO Capital Markets maintained its Market Perform rating and lowered its price target to US$490.00 from US$515.00.<\/p>\n

Moog (MOG.A)<\/strong> \u2014 JPMorgan maintained its Overweight rating and lowered its price target to US$480.00 from US$520.00.<\/p>\n

Morningstar (MORN)<\/strong> \u2014 BMO Capital Markets maintained its Outperform rating and raised its price target to US$237.00 from US$230.00.<\/p>\n

Mosaic (MOS)<\/strong> \u2014 Mizuho maintained its Neutral rating and lowered its price target to US$22.00 from US$25.00.<\/p>\n

Mplx (MPLX)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$64.00 from US$66.00.<\/p>\n

MSC Industrial (MSM)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a US$152.00 price target.<\/p>\n

MSC Industrial Direct (MSM)<\/strong> \u2014 DA Davidson set a US$155.00 price target.<\/p>\n

MSCI (MSCI)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$662.00 from US$700.00.<\/p>\n

Myriad Genetics (MYGN)<\/strong> \u2014 TD Cowen maintained its Hold rating and raised its price target to US$4.50 from US$4.00.<\/p>\n

Natera (NTRA)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$480.00 from US$340.00.<\/p>\n

National Healthcare Properties (NHP)<\/strong> \u2014 Raymond James initiated coverage with an Outperform rating and a US$20.00 price target.<\/p>\n

NatWest Group plc (NWG)<\/strong> \u2014 Barclays upgraded its rating to Overweight from Equal Weight.<\/p>\n

NCR Voyix (VYX)<\/strong> \u2014 Goldman Sachs maintained its Neutral rating and lowered its price target to US$8.00 from US$9.75.<\/p>\n

Netflix (NFLX)<\/strong> \u2014 Huber Research downgraded its rating to Underweight from Buy.<\/p>\n

Netflix (NFLX)<\/strong> \u2014 KeyCorp maintained its Overweight rating and lowered its price target to US$85.00 from US$92.00.<\/p>\n

Nextpower (NXT)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$146.00 from US$147.00.<\/p>\n

NIQ Global Intelligence (NIQ)<\/strong> \u2014 BMO Capital Markets maintained its Outperform rating and raised its price target to US$22.00 from US$20.00.<\/p>\n

NiSource (NI)<\/strong> \u2014 KeyCorp maintained its Overweight rating and lowered its price target to US$48.00 from US$50.00.<\/p>\n

Nurix Therapeutics (NRIX)<\/strong> \u2014 Baird maintained its Outperform rating and raised its price target to US$36.00 from US$33.00.<\/p>\n

Nurix Therapeutics (NRIX)<\/strong> \u2014 Needham & Company LLC reiterated its Buy rating with a US$34.00 price target.<\/p>\n

Nurix Therapeutics (NRIX)<\/strong> \u2014 Oppenheimer maintained its Outperform rating and raised its price target to US$32.00 from US$28.00.<\/p>\n

Nurix Therapeutics (NRIX)<\/strong> \u2014 RBC maintained its Outperform rating and lowered its price target to US$35.00 from US$36.00.<\/p>\n

Nurix Therapeutics (NRIX)<\/strong> \u2014 Stifel Nicolaus set a US$41.00 price target.<\/p>\n

Nurix Therapeutics (NRIX)<\/strong> \u2014 Truist maintained its Buy rating and lowered its price target to US$33.00 from US$34.00.<\/p>\n

O-I Glass (OI)<\/strong> \u2014 RBC maintained its Sector Perform rating and lowered its price target to US$7.00 from US$8.00.<\/p>\n

Olin (OLN)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a US$18.00 price target.<\/p>\n

Olin (OLN)<\/strong> \u2014 RBC maintained its Sector Perform rating and lowered its price target to US$16.00 from US$20.00.<\/p>\n

Ollie’s Bargain Outlet (OLLI)<\/strong> \u2014 Gordon Haskett upgraded its rating to Buy from Accumulate with a US$105.00 price target.<\/p>\n

Omega Healthcare Investors (OHI)<\/strong> \u2014 Barclays maintained its Underweight rating and lowered its price target to US$48.00 from US$50.00.<\/p>\n

Omega Healthcare Investors (OHI)<\/strong> \u2014 UBS maintained its Buy rating and lowered its price target to US$52.00 from US$54.00.<\/p>\n

Once Upon A Farm (OFRM)<\/strong> \u2014 TD Cowen maintained its Hold rating and lowered its price target to US$18.00 from US$20.00.<\/p>\n

ONEOK (OKE)<\/strong> \u2014 Jefferies reiterated its Hold rating with a US$94.00 price target.<\/p>\n

Orion Group (ORN)<\/strong> \u2014 JPMorgan maintained its Overweight rating and lowered its price target to US$14.00 from US$16.00.<\/p>\n

Orion180 Insurance Group (OIG)<\/strong> \u2014 Citigroup initiated coverage with a Market Outperform rating.<\/p>\n

Orion180 Insurance Group (OIG)<\/strong> \u2014 Citizens initiated coverage with a Mkt Outperform rating and a US$20.00 price target.<\/p>\n

Orion180 Insurance Group (OIG)<\/strong> \u2014 Deutsche Bank initiated coverage with a Buy rating and a US$12.90 price target.<\/p>\n

Orion180 Insurance Group (OIG)<\/strong> \u2014 Goldman Sachs initiated coverage with a Buy rating and a US$13.00 price target.<\/p>\n

Orion180 Insurance Group (OIG)<\/strong> \u2014 Raymond James initiated coverage with a Mkt Perform rating.<\/p>\n

Orion180 Insurance Group (OIG)<\/strong> \u2014 RBC initiated coverage with an Outperform rating and a US$15.00 price target.<\/p>\n

Orion180 Insurance Group (OIG)<\/strong> \u2014 UBS initiated coverage with a Buy rating and a US$14.00 price target.<\/p>\n

Ovintiv (OVV)<\/strong> \u2014 RBC maintained its Outperform rating and raised its price target to US$90.00 from US$85.00.<\/p>\n

Pacific Gas & Electric (PCG)<\/strong> \u2014 UBS reiterated its Neutral rating.<\/p>\n

Palisade Bio (PALI)<\/strong> \u2014 HC Wainwright reiterated its Buy rating with a US$7.00 price target.<\/p>\n

Patrick Industries (PATK)<\/strong> \u2014 BMO Capital Markets maintained its Outperform rating and lowered its price target to US$100.00 from US$120.00.<\/p>\n

Paycom Software (PAYC)<\/strong> \u2014 Barclays maintained its Equal Weight rating and raised its price target to US$250.00 from US$210.00.<\/p>\n

Paylocity (PCTY)<\/strong> \u2014 Barclays maintained its Equal Weight rating and raised its price target to US$162.00 from US$154.00.<\/p>\n

Pegasystems (PEGA)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$43.00 from US$39.00.<\/p>\n

Pegasystems (PEGA)<\/strong> \u2014 Citigroup maintained its Buy rating and lowered its price target to US$52.00 from US$55.00.<\/p>\n

PENN Entertainment (PENN)<\/strong> \u2014 Citigroup reiterated its Market Outperform rating.<\/p>\n

PENN Entertainment (PENN)<\/strong> \u2014 Goldman Sachs set a US$23.00 price target.<\/p>\n

PENN Entertainment (PENN)<\/strong> \u2014 Piper Sandler upgraded its rating to Buy from Neutral with a US$26.00 price target.<\/p>\n

Perimeter Solutions (PRM)<\/strong> \u2014 JPMorgan maintained its Overweight rating and lowered its price target to US$40.00 from US$45.00.<\/p>\n

Pershing Square, Inc. (PS)<\/strong> \u2014 BofA Securities downgraded its rating to Underperform from Neutral and lowered its price target to US$38.00 from US$54.00.<\/p>\n

Pfizer (PFE)<\/strong> \u2014 Guggenheim reiterated its Buy rating.<\/p>\n

Phillips 66 (PSX)<\/strong> \u2014 Citigroup maintained its Neutral rating and raised its price target to US$297.00 from US$217.00.<\/p>\n

Phoenix Education Partners (PXED)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$38.00 from US$40.00.<\/p>\n

Planet Fitness (PLNT)<\/strong> \u2014 KeyCorp reiterated its Overweight rating.<\/p>\n

Powell Industries (POWL)<\/strong> \u2014 JPMorgan maintained its Overweight rating and lowered its price target to US$250.00 from US$300.00.<\/p>\n

PPG Industries (PPG)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a US$136.00 price target.<\/p>\n

Prologis (PLD)<\/strong> \u2014 Scotiabank upgraded its rating to Sector Outperform from Sector Perform with a US$150.00 price target.<\/p>\n

Pulse Biosciences (PLSE)<\/strong> \u2014 Mizuho set a US$55.00 price target.<\/p>\n

Pulse Biosciences (PLSE)<\/strong> \u2014 Oppenheimer maintained its Outperform rating and raised its price target to US$60.00 from US$35.00.<\/p>\n

Qnity Electronics (Q)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a US$211.00 price target.<\/p>\n

Qualys (QLYS)<\/strong> \u2014 Morgan Stanley set a US$200.00 price target.<\/p>\n

Qualys (QLYS)<\/strong> \u2014 TD Cowen maintained its Hold rating and raised its price target to US$200.00 from US$170.00.<\/p>\n

Quanterix (QTRX)<\/strong> \u2014 TD Cowen maintained its Hold rating and raised its price target to US$3.50 from US$3.00.<\/p>\n

QXO (QXO)<\/strong> \u2014 Wells Fargo & Company maintained its Overweight rating and lowered its price target to US$16.00 from US$18.00.<\/p>\n

Raymond James Financial (RJF)<\/strong> \u2014 Truist maintained its Hold rating and lowered its price target to US$166.00 from US$188.00.<\/p>\n

Red Rock Resorts (RRR)<\/strong> \u2014 Goldman Sachs reiterated its Buy rating with a US$65.00 price target.<\/p>\n

Republic Services (RSG)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$219.00 from US$232.00.<\/p>\n

ResMed (RMD)<\/strong> \u2014 Mizuho set a US$240.00 price target.<\/p>\n

Revvity (RVTY)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$175.00 from US$130.00.<\/p>\n

Rexford Industrial Realty (REXR)<\/strong> \u2014 Mizuho upgraded its rating to Outperform from Neutral and raised its price target to US$41.00 from US$38.00.<\/p>\n

Richardson Electronics (RELL)<\/strong> \u2014 Northland Securities set a US$26.00 price target.<\/p>\n

Rio Tinto (RIO)<\/strong> \u2014 Citigroup reiterated its Neutral rating.<\/p>\n

Riskified (RSKD)<\/strong> \u2014 Goldman Sachs maintained its Sell rating and raised its price target to US$7.50 from US$5.50.<\/p>\n

RLJ Lodging Trust (RLJ)<\/strong> \u2014 Barclays maintained its Underweight rating and raised its price target to US$12.00 from US$11.00.<\/p>\n

Robinhood Markets (HOOD)<\/strong> \u2014 Truist maintained its Buy rating and raised its price target to US$134.00 from US$130.00.<\/p>\n

Rogers Communication (RCI)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$35.00 from US$36.00.<\/p>\n

Rollins (ROL)<\/strong> \u2014 JPMorgan maintained its Neutral rating and lowered its price target to US$35.00 from US$40.00.<\/p>\n

Rollins (ROL)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$43.00 from US$45.00.<\/p>\n

RPM Inc (RPM)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a US$107.00 price target.<\/p>\n

RTX (RTX)<\/strong> \u2014 Deutsche Bank downgraded its rating to Hold from Buy with a US$208.00 price target.<\/p>\n

Ryman Hospitality Properties (RHP)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$143.00 from US$147.00.<\/p>\n

S&P Global (SPGI)<\/strong> \u2014 BMO Capital Markets maintained its Outperform rating and lowered its price target to US$500.00 from US$505.00.<\/p>\n

Sabra Healthcare REIT (SBRA)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$21.00 from US$23.00.<\/p>\n

Sabra Healthcare REIT (SBRA)<\/strong> \u2014 UBS maintained its Neutral rating and lowered its price target to US$20.00 from US$21.00.<\/p>\n

SAP (SAP)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$243.00 from US$242.00.<\/p>\n

Schrodinger (SDGR)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$31.00 from US$20.00.<\/p>\n

Scorpio Tankers (STNG)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and raised its price target to US$90.00 from US$76.00.<\/p>\n

Seacoast Banking Corporation of Florida (SBCF)<\/strong> \u2014 Raymond James maintained its Outperform rating and lowered its price target to US$36.00 from US$37.00.<\/p>\n

Securitize, Inc. (SECZ)<\/strong> \u2014 Citigroup downgraded its rating to Neutral from Buy and raised its price target to US$14.00 from US$10.00.<\/p>\n

Selective Insurance Group (SIGI)<\/strong> \u2014 Oppenheimer reiterated its Outperform rating with a US$115.00 price target.<\/p>\n

Semtech (SMTC)<\/strong> \u2014 BMO Capital Markets maintained its Outperform rating and raised its price target to US$230.00 from US$155.00.<\/p>\n

SentinelOne (S)<\/strong> \u2014 Needham & Company LLC maintained its Buy rating and raised its price target to US$31.00 from US$26.00.<\/p>\n

ServiceNow (NOW)<\/strong> \u2014 Barclays maintained its Overweight rating and raised its price target to US$160.00 from US$134.00.<\/p>\n

ServiceNow (NOW)<\/strong> \u2014 Evercore reiterated its Outperform rating.<\/p>\n

ServiceNow (NOW)<\/strong> \u2014 Jefferies reiterated its Buy rating.<\/p>\n

ServiceNow (NOW)<\/strong> \u2014 Oppenheimer maintained its Outperform rating and raised its price target to US$165.00 from US$140.00.<\/p>\n

Sherwin-Williams (SHW)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and a US$348.00 price target.<\/p>\n

Shift4 Payments (FOUR)<\/strong> \u2014 BTIG Research maintained its Buy rating and lowered its price target to US$50.00 from US$60.00.<\/p>\n

Shift4 Payments (FOUR)<\/strong> \u2014 Raymond James maintained its Outperform rating and lowered its price target to US$50.00 from US$51.00.<\/p>\n

Silgan (SLGN)<\/strong> \u2014 RBC maintained its Outperform rating and lowered its price target to US$47.00 from US$58.00.<\/p>\n

SmartRent (SMRT)<\/strong> \u2014 B. Riley initiated coverage with a Buy rating and a US$1.75 price target.<\/p>\n

SoFi Technologies (SOFI)<\/strong> \u2014 Goldman Sachs set a US$15.00 price target.<\/p>\n

Solstice Advance Materials (SOLS)<\/strong> \u2014 Barclays initiated coverage with an Overweight rating and a US$73.00 price target.<\/p>\n

Southern (SO)<\/strong> \u2014 JPMorgan maintained its Neutral rating and lowered its price target to US$94.00 from US$101.00.<\/p>\n

Southern (SO)<\/strong> \u2014 KeyCorp maintained its Underweight rating and lowered its price target to US$74.00 from US$79.00.<\/p>\n

Spire Global (SPIR)<\/strong> \u2014 Alliance Global Partners upgraded its rating to Buy from Neutral with a US$15.00 price target.<\/p>\n

SPX Technologies (SPXC)<\/strong> \u2014 Wells Fargo & Company maintained its Overweight rating and lowered its price target to US$243.00 from US$250.00.<\/p>\n

Stellantis (STLA)<\/strong> \u2014 Freedom Broker maintained its Buy rating and lowered its price target to US$6.80 from US$7.50.<\/p>\n

Sun Communities (SUI)<\/strong> \u2014 RBC maintained its Outperform rating and lowered its price target to US$140.00 from US$148.00.<\/p>\n

Syndax Pharmaceuticals (SNDX)<\/strong> \u2014 HC Wainwright reiterated its Buy rating with a US$38.00 price target.<\/p>\n

T. Rowe Price Group (TROW)<\/strong> \u2014 BMO Capital Markets maintained its Market Perform rating and lowered its price target to US$110.00 from US$120.00.<\/p>\n

T. Rowe Price Group (TROW)<\/strong> \u2014 JPMorgan maintained its Underweight rating and lowered its price target to US$106.00 from US$107.00.<\/p>\n

Tandem Diabetes Care (TNDM)<\/strong> \u2014 Mizuho set a US$18.00 price target.<\/p>\n

Targa Resources (TRGP)<\/strong> \u2014 Citigroup maintained its Buy rating and raised its price target to US$325.00 from US$303.00.<\/p>\n

Targa Resources (TRGP)<\/strong> \u2014 Goldman Sachs reiterated its Buy rating with a US$322.00 price target.<\/p>\n

Target (TGT)<\/strong> \u2014 Evercore set a US$165.00 price target.<\/p>\n

Taylor Devices (TAYD)<\/strong> \u2014 Freedom Broker changed its rating to Hold from Buy and lowered its price target to US$65.00 from US$70.00.<\/p>\n

TechnipFMC (FTI)<\/strong> \u2014 UBS initiated coverage with a Buy rating and a US$89.00 price target.<\/p>\n

Telefonica Brasil (VIV)<\/strong> \u2014 BofA Securities upgraded its rating to Neutral from Underperform.<\/p>\n

TELUS (TU)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$10.00 from US$11.00.<\/p>\n

The Descartes Systems Group (DSGX)<\/strong> \u2014 BMO Capital Markets maintained its Market Perform rating and raised its price target to US$90.00 from US$82.00.<\/p>\n

The Hanover Insurance Group (THG)<\/strong> \u2014 Oppenheimer reiterated its Outperform rating with a US$260.00 price target.<\/p>\n

Thermo Fisher Scientific (TMO)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$760.00 from US$675.00.<\/p>\n

Thomson Reuters (TRI)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$110.00 from US$116.00.<\/p>\n

Thor Industries (THO)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$70.00 from US$76.00.<\/p>\n

TIM S.A. (TIMB)<\/strong> \u2014 BofA Securities upgraded its rating to Neutral from Underperform.<\/p>\n

TotalEnergies (TTE)<\/strong> \u2014 TD Cowen maintained its Buy rating and lowered its price target to US$105.00 from US$108.00.<\/p>\n

Tractor Supply (TSCO)<\/strong> \u2014 Citigroup maintained its Buy rating and raised its price target to US$38.00 from US$37.00.<\/p>\n

TransMedics Group (TMDX)<\/strong> \u2014 Canaccord Genuity maintained its Buy rating and lowered its price target to US$94.00 from US$95.00.<\/p>\n

TransUnion (TRU)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$97.00 from US$106.00.<\/p>\n

TransUnion (TRU)<\/strong> \u2014 Needham & Company LLC maintained its Buy rating and lowered its price target to US$85.00 from US$100.00.<\/p>\n

TTM Technologies (TTMI)<\/strong> \u2014 Truist maintained its Buy rating and raised its price target to US$231.00 from US$224.00.<\/p>\n

Twist Bioscience (TWST)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$190.00 from US$115.00.<\/p>\n

Unilever (UL)<\/strong> \u2014 TD Cowen maintained its Buy rating and lowered its price target to US$74.00 from US$76.00.<\/p>\n

United Dominion Realty Trust (UDR)<\/strong> \u2014 RBC maintained its Sector Perform rating and lowered its price target to US$37.00 from US$40.00.<\/p>\n

UnitedHealth Group (UNH)<\/strong> \u2014 UBS reiterated its Outperform rating.<\/p>\n

Unity Bancorp (UNTY)<\/strong> \u2014 DA Davidson reiterated its Buy rating with a US$68.00 price target.<\/p>\n

Unity Software (U)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and raised its price target to US$55.00 from US$50.00.<\/p>\n

Upstart (UPST)<\/strong> \u2014 Goldman Sachs maintained its Neutral rating and lowered its price target to US$28.00 from US$39.00.<\/p>\n

V.F. Corp (VFC)<\/strong> \u2014 Piper Sandler upgraded its rating to Overweight from Neutral and raised its price target to US$20.00 from US$16.00.<\/p>\n

V.F. Corp (VFC)<\/strong> \u2014 Truist upgraded its rating to Buy from Hold and raised its price target to US$20.00 from US$14.00.<\/p>\n

Vail Resorts (MTN)<\/strong> \u2014 Ladenburg Thalmann initiated coverage with a Buy rating and a US$192.00 price target.<\/p>\n

Vale (VALE)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$15.00 from US$17.00.<\/p>\n

Valero Energy (VLO)<\/strong> \u2014 Citigroup maintained its Neutral rating and raised its price target to US$485.00 from US$302.00.<\/p>\n

Varonis Systems (VRNS)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$56.00 from US$53.00.<\/p>\n

Ventas (VTR)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$91.00 from US$102.00.<\/p>\n

Verisk Analytics (VRSK)<\/strong> \u2014 BMO Capital Markets maintained its Outperform rating and lowered its price target to US$217.00 from US$248.00.<\/p>\n

Verisk Analytics (VRSK)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$215.00 from US$235.00.<\/p>\n

Verra Mobility (VRRM)<\/strong> \u2014 JPMorgan maintained its Neutral rating and lowered its price target to US$5.00 from US$6.00.<\/p>\n

Vertex (VERX)<\/strong> \u2014 TD Cowen maintained its Buy rating and lowered its price target to US$15.00 from US$16.00.<\/p>\n

Viking Holdings Ltd (VIK)<\/strong> \u2014 Barclays upgraded its rating to Overweight from Equal Weight with a US$102.00 price target.<\/p>\n

Viper Energy (VNOM)<\/strong> \u2014 Mizuho set a US$57.00 price target.<\/p>\n

Vital Farms (VITL)<\/strong> \u2014 TD Cowen maintained its Hold rating and lowered its price target to US$8.00 from US$11.00.<\/p>\n

Vivmark Residential Common Shares of Beneficial Interest (VMRK)<\/strong> \u2014 RBC maintained its Sector Perform rating and lowered its price target to US$67.00 from US$71.00.<\/p>\n

Vulcan Materials (VMC)<\/strong> \u2014 JPMorgan maintained its Neutral rating and lowered its price target to US$300.00 from US$320.00.<\/p>\n

Waste Connections (WCN)<\/strong> \u2014 Morgan Stanley maintained its Overweight rating and lowered its price target to US$195.00 from US$205.00.<\/p>\n

Waste Management (WM)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$220.00 from US$230.00.<\/p>\n

Waters (WAT)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$515.00 from US$475.00.<\/p>\n

WEC Energy Group (WEC)<\/strong> \u2014 KeyCorp maintained its Overweight rating and lowered its price target to US$111.00 from US$117.00.<\/p>\n

Wells Fargo & Company (WFC)<\/strong> \u2014 Goldman Sachs set a US$94.00 price target.<\/p>\n

Welltower (WELL)<\/strong> \u2014 Barclays maintained its Equal Weight rating and lowered its price target to US$246.00 from US$259.00.<\/p>\n

West Pharmaceutical Services (WST)<\/strong> \u2014 TD Cowen maintained its Buy rating and raised its price target to US$420.00 from US$410.00.<\/p>\n

Westlake (WLK)<\/strong> \u2014 RBC maintained its Outperform rating and lowered its price target to US$74.00 from US$95.00.<\/p>\n

Westlake Corporation (WLK)<\/strong> \u2014 Barclays initiated coverage with an Underweight rating and a US$66.00 price target.<\/p>\n

Winnebago Industries (WGO)<\/strong> \u2014 Citigroup maintained its Neutral rating and lowered its price target to US$24.00 from US$29.00.<\/p>\n

Wintrust Fin (WTFC)<\/strong> \u2014 Deutsche Bank initiated coverage with a Buy rating and a US$175.00 price target.<\/p>\n

Wise Group (WSE)<\/strong> \u2014 UBS maintained its Buy rating and raised its price target to US$17.25 from US$16.00.<\/p>\n

Wynn Resorts (WYNN)<\/strong> \u2014 Goldman Sachs set a US$102.00 price target.<\/p>\n

Xcel Energy (XEL)<\/strong> \u2014 KeyCorp maintained its Overweight rating and lowered its price target to US$87.00 from US$90.00.<\/p>\n

XPLR Infrastructure (XIFR)<\/strong> \u2014 Morgan Stanley maintained its Underweight rating and lowered its price target to US$11.00 from US$12.00.<\/p>\n

Xylem (XYL)<\/strong> \u2014 Barclays maintained its Overweight rating and lowered its price target to US$139.00 from US$159.00.<\/p>\n

Yelp (YELP)<\/strong> \u2014 Morgan Stanley maintained its Underweight rating and lowered its price target to US$17.00 from US$24.00.<\/p>\n

YETI Holdings (YETI)<\/strong> \u2014 Ladenburg Thalmann initiated coverage with a Buy rating and a US$52.00 price target.<\/p>\n

Zapata Quantum (ZPTA)<\/strong> \u2014 Chardan initiated coverage with a Buy rating and a US$1.00 price target.<\/p>\n

Zenas BioPharma (ZBIO)<\/strong> \u2014 HC Wainwright reiterated its Buy rating with a US$44.00 price target.<\/p>\n

Zillow Group (Z)<\/strong> \u2014 Morgan Stanley maintained its Equal Weight rating and lowered its price target to US$35.00 from US$60.00.<\/p>\n","protected":false},"excerpt":{"rendered":"

Analyst Ratings (USA) Today’s analyst outlook was selectively positive but cautious on valuations. New coverage leaned bullish, with 40 of 57 initiations rated a…<\/p>\n","protected":false},"author":3,"featured_media":21803,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-76211","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"\nU.S. Analyst Updates: October 13th, 2026 | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"U.S. Analyst Updates: October 13th, 2026\" \/>\n<meta property=\"og:description\" content=\"Analyst Ratings (USA) Today’s analyst outlook was selectively positive but cautious on valuations. New coverage leaned bullish, with 40 of 57 initiations rated a…\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-14T04:43:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2022\/09\/StockTargetAdvisor-Frame-2-5.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"32 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"U.S. Analyst Updates: October 13th, 2026\",\"datePublished\":\"2026-10-14T04:43:44+00:00\",\"dateModified\":\"2026-10-14T04:43:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/\"},\"wordCount\":7244,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News & Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/\",\"name\":\"U.S. Analyst Updates: October 13th, 2026 | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2026-10-14T04:43:44+00:00\",\"dateModified\":\"2026-10-14T04:43:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"U.S. Analyst Updates: October 13th, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"U.S. Analyst Updates: October 13th, 2026 | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/","og_locale":"en_US","og_type":"article","og_title":"U.S. Analyst Updates: October 13th, 2026","og_description":"Analyst Ratings (USA) Today’s analyst outlook was selectively positive but cautious on valuations. New coverage leaned bullish, with 40 of 57 initiations rated a…","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2026-10-14T04:43:44+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2022\/09\/StockTargetAdvisor-Frame-2-5.jpg","type":"image\/jpeg"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"32 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"U.S. Analyst Updates: October 13th, 2026","datePublished":"2026-10-14T04:43:44+00:00","dateModified":"2026-10-14T04:43:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/"},"wordCount":7244,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News & Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/","name":"U.S. Analyst Updates: October 13th, 2026 | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2026-10-14T04:43:44+00:00","dateModified":"2026-10-14T04:43:44+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/u-s-analyst-updates-october-13th-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"U.S. Analyst Updates: October 13th, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/76211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=76211"}],"version-history":[{"count":3,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/76211\/revisions"}],"predecessor-version":[{"id":76217,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/76211\/revisions\/76217"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/21803"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=76211"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=76211"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=76211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}